Mesothelioma Epidemiology, Pathogenesis, Emerging Treatments and Pre-Clinical Models
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".
Deadline for manuscript submissions: 25 June 2024 | Viewed by 209
Special Issue Editor
Interests: cancer; mesothelioma; cell cycle; CDK inhibitors; p53; RB proteins; oncolytic viruses; microRNAs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to a Special Issue on ‘Mesothelioma Epidemiology, Pathogenesis, Emerging Treatments and Pre-clinical Models’. Mesothelioma is a rare and aggressive disease mainly due to exposure to asbestos or other toxic fibres. Unfortunately, there is no current curative modality effective against this cancer, and therefore, the prognosis remains dismal. Despite advancements in understanding the molecular mechanisms underlying this disease, there is still an urgent need for further research to facilitate early diagnosis and to identify new treatments (or rationale drug combinations) which could significantly improve patient outcomes.
This Special Issue aims to publish cutting-edge research and advancements in the field of mesothelioma to address these aforementioned challenges. We welcome submissions of both original research articles and reviews. Some suggested research areas include, but are not limited to, the following:
- Epidemiology and risk factors of mesothelioma;
- Molecular mechanisms underlying mesothelioma pathogenesis;
- Novel diagnostic approaches and biomarkers for early detection;
- Advancements in surgical techniques and therapeutic interventions;
- Emerging targeted therapies and immunotherapies for mesothelioma;
- Pre-clinical models of mesothelioma
Dr. Francesca Pentimalli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mesothelioma
- epidemiology
- pathogenesis
- emerging treatments
- risk factors
- biomarkers
- surgical techniques
- targeted therapies
- immunotherapies
- pre-clinical models
